These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9295860)

  • 21. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case for economic analyses.
    Carlson LE; Bultz BD
    Psychooncology; 2004 Dec; 13(12):837-49; discussion 850-6. PubMed ID: 15578622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
    Meyers FJ; Linder J; Beckett L; Christensen S; Blais J; Gandara DR
    J Pain Symptom Manage; 2004 Dec; 28(6):548-56. PubMed ID: 15589080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of advanced nursing care on quality of life and cost outcomes of women diagnosed with breast cancer.
    Ritz LJ; Nissen MJ; Swenson KK; Farrell JB; Sperduto PW; Sladek ML; Lally RM; Schroeder LM
    Oncol Nurs Forum; 2000 Jul; 27(6):923-32. PubMed ID: 10920832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost of childhood cancer from the family's perspective: a critical review.
    Tsimicalis A; Stevens B; Ungar WJ; McKeever P; Greenberg M
    Pediatr Blood Cancer; 2011 May; 56(5):707-17. PubMed ID: 21370401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring costs: administrative claims data, clinical trials, and beyond.
    Etzioni R; Riley GF; Ramsey SD; Brown M
    Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic analysis of adverse events in cancer treatment].
    Koinuma N; Takeyoshi H
    Nihon Rinsho; 2003 Jun; 61(6):1030-8. PubMed ID: 12806956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness, cancer burden and financial crisis: a perfect storm.
    Belda-Iniesta C
    Clin Transl Oncol; 2012 Oct; 14(10):713-4. PubMed ID: 22996423
    [No Abstract]   [Full Text] [Related]  

  • 32. The economic impact of cancer.
    Leake AR
    Nurse Pract Forum; 1995 Dec; 6(4):207-14. PubMed ID: 8547810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement and valuation of quality of life in economic appraisal of cancer treatment.
    Uyl-de Groot CA; Rutten FF; Bonsel GJ
    Eur J Cancer; 1994; 30A(1):111-7. PubMed ID: 8142152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation.
    Rejeb O; Pilet C; Hamana S; Xie X; Durand T; Aloui S; Doly A; Biron P; Perrier L; Augusto V
    Health Care Manag Sci; 2018 Jun; 21(2):204-223. PubMed ID: 28516345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cancer therapy--economic aspects].
    Catane R; Catane H; Rozencweig M
    Harefuah; 1995 Feb; 128(3):182-5. PubMed ID: 7759013
    [No Abstract]   [Full Text] [Related]  

  • 36. Ought cancer treatments to be immune from socio-economic evaluation? An epilogue.
    Culyer AJ; Jönsson B
    Eur J Cancer; 1993; 29A Suppl 7():S31-2. PubMed ID: 8312061
    [No Abstract]   [Full Text] [Related]  

  • 37. The future cost of cancer in South Africa: An interdisciplinary cost management strategy.
    Sartorius K; Sartorius B; Govender PS; Sharma V; Sherriff A
    S Afr Med J; 2016 Sep; 106(10):949-950. PubMed ID: 27725010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economic evaluation of cancer treatments and programmes.
    Goddard M; Drummond M
    Eur J Cancer; 1991; 27(10):1191-6. PubMed ID: 1835583
    [No Abstract]   [Full Text] [Related]  

  • 39. Health-economic issues in nocturia.
    Kobelt G
    BJU Int; 1999 Dec; 84 Suppl 1():29-32. PubMed ID: 10674892
    [No Abstract]   [Full Text] [Related]  

  • 40. How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.
    Zafar SY; Newcomer LN; McCarthy J; Fuld Nasso S; Saltz LB
    Am Soc Clin Oncol Educ Book; 2017; 37():35-39. PubMed ID: 28561659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.